Vol 6, No 1 (2020)
Letter to the Editor
Published online: 2020-07-01
Czy chlorochina i hydroksychlorochina pomogą opanować pandemię COVID-19?
DOI: 10.5603/FR.2020.0007
Forum Reumatol 2020;6(1):59-61.
Abstract
–
References
- Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 [Epub ahead of print].
- Keyaerts E, Vijgen L, Maes P, et al. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004; 323(1): 264–268.
- Gao J, Tian Z, Yang Xu. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020; 14(1): 72–73.
- Yao X, Zhang M, Cui C, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020.
- Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 [Epub ahead of print]: 105949.
![](https://journals.viamedica.pl/plugins/generic/popups/images/icons/close.png)